Covaxin to use ViroVax's adjuvant Alhydroxiquim-II to boost immune response

Vaccine maker Bharat Biotech on Monday anunced its vel coronavirus vaccine (under development) Covaxin, which was approved for human trials, will use juvant Alhydroxiquim-II to boost immune response and longer-lasting immunity.

According to a press release issued by city-based vaccine invator, techlogy is being used under a licensing agreement with Kansas-based ViroVax LLC. Covaxin is an inactivated vaccine derived from a strain of SARS-CoV-2 virus, isolated at National Institute of Virology (NIV), Pune, an Indian virology research institute.

inactivated virus is formulated with ViroVax's juvant to produce vaccine candidate, it said. Bharat Biotech is currently conducting Phase II human trials of Covaxin after receiving approval from Drug Controller General of India (DCGI).

"re is critical need for development and availability of juvants that elucidate mechanisms of action inducing greater antibody responses to vaccine antigens, thus resulting in long-term protection against pathogens. juvants also enhance sustainability of global vaccine supply on account of ir antigen-sparing effect," Krishna Ella, Chairman and Managing Director of Bharat Biotech,said.

"Our partnership with ViroVax resonates with Bharat Biotech's relentless efforts towards developing safe and effective vaccines coupled with long term immunity," he ded. "ViroVax is delighted to partner with Bharat Biotech. This has been possible because of support from National Institutes of Health," Sunil David, Founder of ViroVax said.

This story has t been edited by www.republicworld.com and is auto-generated from a syndicated feed